

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 October 2021 (07.10.2021)



(10) International Publication Number
WO 2021/202977 A1

(51) International Patent Classification:

A61K 31/519 (2006.01) C07D 265/28 (2006.01)
C07D 207/02 (2006.01)

(21) International Application Number:

PCT/US2021/025547

(22) International Filing Date:

02 April 2021 (02.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/004,799 03 April 2020 (03.04.2020) US

(71) Applicant: **BIOCRYST PHARMACEUTICALS, INC.**
[US/US]; 4505 Emperor Blvd., Suite 200, Durham, NC
27703 (US).

(72) Inventors: **KOTIAN, Pravin, L.**; 1139 Magnolia Run,
Hoover, AL 35226 (US). **BABU, Yarlagadda, S.**; 4836
Southlake Parkway, Birmingham, AL 35244 (US). **WU,**
Minwan; 2709 Paden Trail, Vestavia Hills, AL 35226 (US).
DANG, Zhao; 1226 Parliament Lane, Vestavia Hills, AL
35216 (US). **NGUYEN, Trung, Xuan**; 5066 Park Side Circle,
Hoover, AL 35244 (US). **RAMAN, Krishnan**; 3739
Spearman Drive, Birmingham, AL 35216 (US).

(74) Agent: **GORDON, Dana, M.** et al.; Foley Hoag LLP, Sea-
port West, 155 Seaport Boulevard, Boston, MA 02210-2600
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS



(I)

(57) Abstract: Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

WO 2021/202977 A1